Study identifies key molecular step in mitochondrial division4 October 2024A key molecular step required for the division of damaged mitochondria - essential for cell health - has been identified by a University of Bristol-led study. The finding has the potential to establish how mitochondrial dysfunction goes wrong in common neurodegenerative diseases, such as Parkinson's and Alzheimer's.
Boosting key protein in eye cells could prevent age-related vision loss, finds international team5 June 2024Increasing the levels of a key protein in the cells at the back of the eye could help protect against the leading cause of vision loss among older adults, finds a new discovery made by researchers from the UK, US, Germany and Australia. The University of Bristol-led findings are published today [5 June] in Science Translational Medicine and featured on the front cover.
Study highlights potential new approach for early intervention for diabetic patients at risk of kidney disease27 March 2024Researchers at the University of Bristol have uncovered a mechanism by which a hormone can protect the blood vessels in the kidneys from the damage caused by diabetes. In doing so, the team has identified a potential early treatment strategy to prevent or slow progression of kidney disease in people with diabetes. The study, part-funded by Kidney Research UK, is published in Diabetes.
Scientists reveal why blueberries are blue7 February 2024Tiny external structures in the wax coating of blueberries give them their blue colour, researchers at the University of Bristol can reveal.
New drug could prevent diabetic eye and kidney disease in people with diabetes2 February 2024New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is published in Cardiovascular Diabetology.
New research demonstrates the ability of ADDomer™ to tackle viral infections29 November 2023New research has demonstrated the potential for the ADDomer ™ platform to produce thermostable vaccines and reagents to tackle viral infections The study led by the University of Bristol and Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer platform, is published in Antibody Therapeutics today [29 November].
